A urinary tract infection is an infection of the bladder, urethra, ureter, and kidneys caused by the growth of a microbial pathogen in the bladder or kidneys. Urinary tract infections are classified into two types: uncomplicated urinary tract infections and complicated urinary tract infections.
The global urinary tract infection treatment market is expected to be worth US$ 10,170.8 million in 2017 and is expected to reach US$ 11,827.8 million in 2027.
The increased incidences of urinary tract infection is expected to drive the global urinary tract infection market growth during the forecast period. For instance, according to the February 2019 study “Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda,” the incidence of Urinary tract infections was 32.2 % among the participants in the study.
Furthermore, research and developments of new antibiotics classes for urinary tract infections is expected to aid in the global urinary tract infection treatment market growth over the forecast period. For instance, during the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo in August 2020, researchers from California Polytechnic State University announced the discovery of a new antibiotics class for urinary tract infections that target bacterial iron acquisition.
Quinolones accounted for the largest share in the global urinary tract infection treatment market in 2019, representing 37.7 % of the market share, trailed by Cephalosporin and Penicillin & Combinations, respectively.
Highly regulated requirements are expected to restrict the global urinary tract infection treatment market growth over the forecast period. An antibiotic clinical trial varies from other therapeutic drugs in terms of clinical approval approaches such as clinical trial design, interpretation, and analysis. To get clearance, the sponsor must perform non-inferiority trials in conjunction with existing registered antibacterial drugs. Clinical trials for the development of antibacterial drugs are complicated and need an informed, ethical, and scientific approach. Such factors are expected to have a negative influence on the global urinary tract infection treatment market growth during the forecast period.
Urinary tract infection research and development is expected to provide attractive growth possibilities for companies in the global urinary tract infection treatment market. For example, in May 2020, researchers from Vrije Universiteit Amsterdam in the Netherlands reported that by using an electronic nose and volatile organic compounds profiling, urinary tract infections can be distinguished from non-urinary tract infections in an intention-to-diagnose high-risk pediatric population.
Furthermore, the increasing incidences of urinary tract infections in emerging nations is expected to propel the global urinary tract infection treatment market growth over the forecast period. Furthermore, the increasing frequency of urinary tract infections in emerging nations is likely to help market expansion. For instance, according to the study, ‘Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI,’ which was conducted at the Microbiology department of a tertiary health care hospital in Mumbai and published in 2018, the total incidence of Urinary tract infection was 33.54 %, with 66.78 % being women and 33.22 % being men.
The global urinary tract infection treatment market in 2019 was worth US$ 9,971.9 million and is expected to rise to US$ 11,827.8 Million by 2027 registering at a CAGR of 2.2% during the forecast period of 2020 and 2027.
Key players in the global urinary tract infection treatment market are focusing on the research and developments of new treatments to grow their product offerings. For instance, Allecra Therapeutics, a drug company based in France, reported in February 2020 that its Exblifep (cefepime-enmetazobactam), a combination of enmetazobactam, a new extended-spectrum beta-lactamase inhibitor, and the fourth-generation cephalosporin cefepime, met primary endpoints in clinical trials for complicated urinary tract infections (cUTI).
Some of the key market players are also concentrating on collaboration strategies to increase their market share. For instance, Healthy.io, a developer of smartphone camera-based solutions, announced in July 2019 a collaboration with Walgreens Boots Alliance, Inc. to place Healthy.io’s Dip UTI test kits in Boots pharmacies across the U.K.
Some of the key players contributing to the global urinary tract infection treatment market are, Spero Therapeutics, Inc., Boehringer Ingelheim, Iterum Therapeutics plc, Shionogi Inc., Johnson & Johnson, Venatorx Pharmaceuticals, GlaxoSmithKline, Novartis AG, Cipla Ltd., Healthy.io, F. Hoffmann-La Roche Ltd., Allecra Therapeutics, Bayer AG, Pfizer Inc., and AstraZeneca Plc.
Major players in the global urinary tract infection treatment market are focusing on the research and development of new therapies to increase their product offerings. For instance, Spero Therapeutics, Inc. reported in May 2020 that patient enrolment in their Phase 3 clinical trial had been completed, of tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), ADAPT-PO, and acute pyelonephritis (AP).
Reasons to Purchase this Report
• To gain an in-depth understanding of Urinary Tract Infection Treatment market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, Urinary Tract Infection Treatment market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Buy This Complete Business Report
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Regulatory Scenario
- PEST Analysis
- COVID-19 Impact Analysis
- Market Dynamics
- Global Urinary Tract Infection Treatment Market, By Drug Type, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Penicillin & Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Amoxicillin
- Amoxicillin+ Clavulanate
- Potassium”
- Others
- Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Ciprofloxacin
- Levofloxacin
- Nalidixic acid
- Norfloxacin
- Others
- Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Ceftriaxone
- Cefuroxime
- Cefixime
- Cephalexin
- Aminoglycoside Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Amikacin
- Gentamicin
- “Sulphonamides (Sulfamethoxazole +
- Trimethoprim)”
- Azoles and Amphotericin B
- Tetracycline (Doxycycline)
- Nitrofurans (Nitrofurantoin)
- Other
- Introduction
- Global Urinary Tract Infection Treatment Market, By Disease Indication, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Recurring Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Uncomplicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Neurogenic Bladder Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Urinary Tract Infection Treatment Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Urinary Tract Infection Treatment Market, By Regions, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Cipla Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Iterum Therapeutics plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allecra Therapeutics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shionogi Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Spero Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Venatorx Pharmaceuticals.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd.
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837